Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
March Against Monsanto our kids." Out of her anger, frustration, and concerns for the health of her children, Canal developed the idea for a "March Against Monsanto" social media campaign. Canal started a Facebook social media campaign on February 28, 2013. She stated: "For too long, Monsanto has been the benefactor of corporate subsidies and political favoritism ... Organic and small farmers suffer losses while Monsanto continues to forge its monopoly over the world's food supply, including exclusive patenting rights over seeds and genetic makeup." She argued that Monsanto benefited from corporate subsidies and political favoritism and that its patent rights over the